Presentation is loading. Please wait.

Presentation is loading. Please wait.

Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound.

Published byChristian Malone Modified over 6 years ago

Similar presentations

Presentation on theme: "Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound."— Presentation transcript:

1 Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound to the 5-HT2A receptor. Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound to the 5-HT2A receptor. Ivacaftor, iva-M6 and residues within the receptor cavity are shown in ball-and-stick representation. The 5-HT2C and 5-HT2A receptors are shown in cartoon ribbon representation. The labelled side chains within the binding cavity represent contacts within 4 Å of the docked molecules. Elena K. Schneider et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "Molecular docking models of a) ivacaftor bound to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor and b) ivacaftorcarboxylate (iva-M6) bound."

Similar presentations

Figure 8. Docking of major catechins to the binding cavity in the umami receptor along with their corresponding molecular interactions; Three representative.

Figure 8. Docking of major catechins to the binding cavity in the umami receptor along with their corresponding molecular interactions; Three representative.
CYB561 homology modeling. CYB561 homology modeling.A, Close-up of mutation G88R in CYB561. The protein is shown in ribbon presentation in gray, the heme.

CYB561 homology modeling. CYB561 homology modeling.A, Close-up of mutation G88R in CYB561. The protein is shown in ribbon presentation in gray, the heme.
Structurally ordered water molecules in the pore of GLIC

Structurally ordered water molecules in the pore of GLIC
Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.

Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.
Conformational changes of the ion-permeation pathway.

Conformational changes of the ion-permeation pathway.
Echocardiography view

Echocardiography view
Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.
Structures of natural cytotoxicity receptors.

Structures of natural cytotoxicity receptors.
Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.

Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
The Structure of HLA-DM, the Peptide Exchange Catalyst that Loads Antigen onto Class II MHC Molecules during Antigen Presentation  Lidia Mosyak, Dennis.

The Structure of HLA-DM, the Peptide Exchange Catalyst that Loads Antigen onto Class II MHC Molecules during Antigen Presentation  Lidia Mosyak, Dennis.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.

Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Survival without tracheostomy

Survival without tracheostomy
A, structure drawing of LY

A, structure drawing of LY
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
AG-221 structure and binding characteristics.

AG-221 structure and binding characteristics.

Similar presentations

Ads by Google